PEGBIO CO-B (02565) surged over 15% again, reaching a high of HK$37 and setting a new listing record. As of press time, the stock was up 14.5% to HK$36.64 with a turnover of HK$25.9996 million.

On the news front, Novo Nordisk's semaglutide recently received approval for a new MASH indication, driving up heat in the GLP-1 sector. Public information shows that PEGBIO CO-B is a biotechnology company focused on independent research and development of innovative therapies for chronic diseases. The company has 6 drugs in its research pipeline, with 4 related to GLP-1 drugs, targeting indications primarily in obesity, overweight, and diabetes areas.

Currently, the company's most promising commercializable product is PB-119, a GLP-1 receptor agonist for weight loss applications. From a market perspective, China, as the world's second-largest pharmaceutical market, simultaneously possesses the world's largest populations of diabetes patients (expected to reach 164 million by 2030) and overweight individuals (expected to reach 200-250 million by 2030), making it a key strategic battleground for both global pharmaceutical giants and domestic enterprises.

As market potential continues to be released, PEGBIO is expected to leverage its differentiated innovation capabilities and its core variety with best-in-class attributes to reshape the domestic T2DM treatment market landscape and accelerate the release of its intrinsic value.